H. Lundbeck A/S (LON:0ND5)
34.72
-0.64 (-1.82%)
At close: Jul 14, 2025
H. Lundbeck Revenue
H. Lundbeck had revenue of 6.24B DKK in the quarter ending March 31, 2025, with 17.91% growth. This brings the company's revenue in the last twelve months to 22.95B, up 13.87% year-over-year. In the year 2024, H. Lundbeck had annual revenue of 22.00B with 10.51% growth.
Revenue (ttm)
22.95B DKK
Revenue Growth
+13.87%
P/S Ratio
1.51
Revenue / Employee
4.02M DKK
Employees
5,707
Market Cap
3.88B GBP
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.00B | 2.09B | 10.51% |
Dec 31, 2023 | 19.91B | 1.67B | 9.13% |
Dec 31, 2022 | 18.25B | 1.95B | 11.95% |
Dec 31, 2021 | 16.30B | -1.37B | -7.77% |
Dec 31, 2020 | 17.67B | 636.00M | 3.73% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
HSBC Holdings | 44.89B |
Shell | 217.54B |
Unilever | 50.25B |
British American Tobacco p.l.c. | 25.87B |
Rolls-Royce Holdings | 18.91B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |
H. Lundbeck News
- 23 days ago - New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine - Benzinga
- 23 days ago - New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine - Benzinga
- 2 months ago - Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers - Seeking Alpha
- 4 months ago - Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan - PRNewsWire
- 6 months ago - Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade) - Seeking Alpha